Retatrutide is a new entrant into the rapidly-expanding space of anti-obesity peptides. It is known as a GGG tri-agonist. This means that retatrutide works at all of the incretin receptors including GLP-1 and GIP as well as the glucagon receptor itself. Research indicates that retatrutide may be the most effective weight loss peptide yet developed, with some studies showing a rapid and sustained weight loss response as high as 24% of total body weight[1]. Retatrutide is thought to promote weight loss by increasing energy expenditure as well as decreasing energy consumption. It does the former via action at the glucagon receptor and the latter through both central and peripheral appetite control.

Последовательность: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3Молекулярная формула: С₂₂₃ЧАС₃₄₃Ф₃Н₄₆О₇₀ Молекулярная масса: 4845,44 г/мольПабХим SID: 474492335Количество CAS: 2381089-83-2Синонимы: LY-3437943, NOP2Y096GV

Что такое Ретатрутид?

Ретатрутид, как уже упоминалось, является триагонистом GGG. Ретатрутид представляет собой одиночный пептид, ацилированный жирными кислотами, который сочетает в себе активности GCGR, GIPR и GLP-1R. Он основан на сильно модифицированном пептидном остове GIP. Модификация этой основной цепи позволила ретатрутиду связываться с альбумином в кровотоке. Это, в свою очередь, означает, что препарат остается в крови в течение длительного периода времени. Этот увеличенный период полувыведения означает, что ретатрутид нужно принимать только один раз в неделю. Широкий спектр активности позволяет ретатрутиду связываться с несколькими различными инкретиновыми рецепторами и оказывать следующие специфические эффекты.

• Пептидный рецептор желудочного ингибитора (GIPR): также называемый глюкозозависимым инсулинотропным полипептидным рецептором. Этот рецептор обнаружен в центральной нервной системе, а также во всем желудочно-кишечном тракте и организме. По-видимому, он играет важную роль в центральных механизмах, влияющих на чувство голода, и, как полагают, играет роль в отправке сигналов о «сытости» из желудочно-кишечного тракта в мозг.

• Глюкагоноподобный пептидный рецептор-1 (GLP-1R). Активация этого рецептора приводит к замедлению опорожнения желудка. Замедленное опорожнение желудка посылает в мозг сигналы о необходимости уменьшить потребление пищи и, следовательно, может помочь контролировать потребление энергии. Пептиды, нацеленные на этот рецептор, изначально были разработаны для лечения диабета 2 типа, но с тех пор было обнаружено, что они улучшают потерю веса и снижают риск некоторых форм сердечно-сосудистых заболеваний. Их исследуют на предмет лечения депрессии, нарушений системы вознаграждения (например, алкоголизма, зависимости), синдрома поликистозных яичников и неалкогольной жировой болезни печени.

• Рецептор глюкагона (GCGR). Рецептор глюкагона встречается в основном в печени и почках. Мутации этого рецептора связаны с некоторыми формами диабета 2 типа. Связываясь с этим рецептором, ретатрутид увеличивает выработку глюкагона, который стимулирует расщепление запасенных форм энергии, таких как жир и гликоген. Это приводит к увеличению основного обмена (даже во время сна), что увеличивает потерю веса в целом и сжигание жира в частности.

Как работает Ретатрутид?

In vivo research, in humans, indicates that retatrutide activates and is a full agonist of all of the incretin receptors including GIPR, GLP-1R, and GCGR. Retatrutide was specifically designed to be highly potent at the GIPR and GLP-1R locations. As a result, retatrutide is one of the most potent incretins available and thus has strong effects on both gastric emptying and the central control of hunger/satiety. Research shows that the bulk of retatrutide’s effects are driven by loss of fat mass that is probably the result of a larger and more prolonged reduction in food intake compared to similar peptides. Decreased food intake, especially as occurs early in the use of the peptide, jump starts fat oxidation. This sets the stage for prolonged weight loss by altering basal metabolism and overcoming the hormonal forces that perpetuate obesity[2]. The bulk of retatrutide’s benefit is a result of its ability to decrease energy intake via delayed gastric emptying and increased control of hunger signals in the central nervous system. That said, the ability of the peptide to increase energy expenditure is also statistically significant and should not be discounted.Эффект ГИПР:(glucose-dependent insulinotropic polypeptide receptor) Agonism of the GIPR leads to decreased gastric acid secretion and gastrin release. Gastrin is a peptide hormone that stimulates the release hydrochloric acid and histamine in the stomach. These effects help to slow digestion and reduce transit through the GI tract. As a result, action on the GIPR can lead to increased feelings of fullness.Эффекты GLP-1R:(glucagon-like peptide-1 receptor) Agonism of the GLP-1R is well known to delay gastric emptying. Research in both rodents and humans supports this. Gastric emptying (GE) is an important determinant of the glycemic response following food intake. Research indicates that slowing GE can reduce food intake and thus impact weight loss. Research in mice reveals that GLP-1R is the only receptor of the three to affect GE, and thus the delay of GE caused by retatrutide is no greater than the delay caused by semaglutide, tirzepatide, liraglutide, or any of the other GLP-1R agonists. Interestingly, however, is the difference in dose to achieve full effect on GE. Research shows that retatrutide has the same efficacy as semaglutide at a dose that is more than 30 times smaller[3]. As with semaglutide, however, the effects of retatrutide on GE wane over time. This decrease in effect of a therapeutic over time is referred to as tachyphylaxis and may, in some cases, necessitate a drug holiday to help restore effects.Эффекты GCGR:(G-protein-coupled receptor) It wasn’t fully understood until relatively recently that glucagon plays an important role in regulating hunger and energy expenditure. Research now reveals that glucagon signals the brain from the gut via the vagal nerve. This signaling promotes feelings of fullness and is regulated by glucagon concentrations in the portal circulation of the liver. In mouse models, the administration of glucagon has resulted in a 20% weight loss[4]. Additional research has shown that glucagon can increase energy expenditure. This effect has been observed in both animal and human trials. This particular effect is not mediated through the GCGR, but rather through via FGF21. FGF21 is a protein secrete by the liver that regulated sugar intake and preferences for sweet foods, among a host of other functions. Mutations in this protein have been identified in those with a “sweet tooth” [5]. FGF21 regulates the uptake of glucose by adipocytes (fat cells). Treatment of animals with FGF21 results in increased energy expenditure, fat utilization and lipid excretion. Studies in mice show that activation of FGF21 can lead to a 20% weight reduction primarily via increased fat loss[6]. This occurs without a change in total calorie intake, indicating a change in metabolic rate. Mice given an FGF21 infusion have demonstrated higher energy expenditure both during wakefulness and during sleep. This is likely mediated through effects on mitochondrial activity.

Насколько эффективен Ретатрутид для похудения?

Research indicates that retatrutide is likely the most effect incretin-based peptide for weight loss yet developed. In a study in rodents, for instance, just 10 days of retatrutide treatment leads to decreases in total body weight greater than those seen with semaglutide. This occurs when the peptides are administered at the same doses. If retatrutide is given at a lower dose that semaglutide, then it produces similar weight loss effects but with decreased risk of side effects[3]. Thus, retatrutide may offer an alternative treatment option for those who are somewhat intolerant of the side effects of semaglutide. A phase 2 study in humans has showed that retatrutide can produced significant reductions in body weight. In fact, trial participants given the highest dose of the peptide lose approximately 20 pounds in just 12 weeks[1]. In another trial, individuals treated for 26 weeks showed changes in waist circumference ranging from -2.1 cm to -10.2 cm[7]. In other words, people taking retatrutide in this trial lost anywhere from 1 inch to ~5 inches off of their waist in just 6 months. Finally, in a trial published in the New England Journal of Medicine, weight loss from retatrutide varied in a dose-dependent manner over the 48 weeks of the trial. Individuals given the lowest dose of the peptide lost 8.7% of their total body weight while those given the highest dose lost more than 24% of their total body weight[8]. Similar results were published in a JAMA article as well[9].

Ретатрутид и диабет

В исследованиях фазы 2 ретатрутид привел к значительному снижению уровня гликированного гемоглобина (гемоглобина A1c) [10]. Гемоглобин – это соединение крови, которое переносит кислород. Гликированный гемоглобин — это гемоглобин, химически связанный с сахаром. Высокий уровень гликированного гемоглобина вызван хронически высоким уровнем сахара в крови и связан с диабетом. Фактически, уровни HBA1c можно использовать для мониторинга долгосрочного контроля уровня сахара в крови у людей, страдающих диабетом. Поддержание этих уровней на низком уровне имеет решающее значение не только для хорошего контроля уровня сахара в крови, но и для предотвращения долгосрочных последствий диабета, включая сердечно-сосудистые заболевания, повреждение нервов, повреждение почек и проблемы с глазами.

Ретатрутид и здоровье сердца

It has long been known that infusing elevated doses of glucagon into those with heart failure can augment heart rate and cardiac contractility. Pharmacological administration of glucagon, typically in milligram quantities, is commonly employed in addressing acute cardiac depression resulting from overdoses of calcium channel antagonists or beta-blockers, despite limited research in this area. Interestingly, glucagon concentrations within the normal physiological range seem to have no discernible impact on heart rate or contractility[11]. The impact of retatrutide on heart health has not been directly assessed in humans, but it has been assessed in cynomolgus monkeys. In the past, it was thought that elevated actions of glucagon were associated with diabetes. That is to say, scientists thought that lower glucagon would lead to improved outcomes in diabetes. Thus, monoclonal glucagon antibodies, glucagon receptor antagonists (peptide and non-peptide) and molecules targeting the expression of GCGR have all been tested as potential treatments. Research on these agents, however, revealed a number of major obstacles including limited efficacy, the risk of iatrogenic hypoglycemia, and other safety issues related to lack of specificity of glucagon blockade, immunogenicity and toxicity. This really should not have come as any surprise as the rise in glucagon levels in diabetes is likely a consequence of the disease and not a cause of it. Research also indicates that incretins have beneficial effects on the cardiovascular system by decreasing blood pressure, improving left ventricular function, endothelium-dependent vasodilation, and by increasing endothelial progenitor cells. In other words, glucagon and related molecules appear to improve heart health[12]. Supporting this notion is the fact that a number of incretin agonists (e.g. semaglutide, liraglutide) have been associated with improvements in cardiovascular outcomes in diabetes. As a result, these peptides are now under investigation for direct use in heart disease. Retatrutide is likely to show improved results given its more extensive effects on glucagon levels, but the exact effects will have to await more detailed clinical and benchtop trials. These findings indicate that retatrutide and similar molecules may be beneficial to regeneration in the cardiovascular as well as helping to prevent cardiovascular disease in the first place. As mentioned, a limited, non-clinical cardiovascular study of retatrutide in monkeys has been undertaken. This study revealed higher heart rates at all dose levels with a dose dependent effect overall. At the same time retatrutide was increasing heart rate, it was decreasing blood pressure in the monkeys. Unfortunately, this study was limited in both duration and number of individuals under investigation. Thus, while it can offer some foundation on which to ground speculation, it cannot provide any definitive information about retatrutide and its long-term effects on cardiovascular health.

Краткое описание ретатрутида

Retatrutide is an incretin mimetic and GGG agonist. It binds to glucagon receptors, gastric inhibitory peptide receptors, and glucagon-like peptide-1 receptors. This triple activity has been associated with significant weight loss (24% of body weight at 6 months) in clinical trials. This outcome makes retatrutide the most effective of incretin peptides to date and thus it is under intense investigation as a weight loss agent. There is some hope that retatrutide may also have beneficial cardiovascular effects and might therefore be useful in the treatment of heart disease complicated by diabetes as well as heart disease in general.

Уильям К. Роэлл, доктор философии. получил степень бакалавра микробиологии и биохимии в Университете Майами. Он получил докторскую степень в области клеточной и интегративной физиологии в Медицинской школе Университета Индианы, занимаясь клеточной терапией и изучая метаболические изменения, связанные с созреванием адипоцитов. Присоединившись к Лилли в 2000 году,Уильямworked with multiple drug discovery groups providing innovative approaches to translate therapeutic concepts from bench to bedside. More recently, he has supported efforts in diabetes biomarker discovery and target identification/advancement, impacting discovery and development efforts across Lilly’s Diabetes and Complications portfolio. William and his lab currently are active in drug discovery with a focus on diabetes and obesity. He has a particular interest in mechanisms by which incretin receptor modulation contributes to the profound benefits observed clinically with existing and emerging therapeutics. Dr. William C. Roell is being referenced as one of the leading scientists involved in the research and development of Retatrutide. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

T. Coskunet al., “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept,”Cell Metab., vol. 34, no. 9, pp. 1234-1247.e9, Sep. 2022, doi: 10.1016/j.cmet.2022.07.013. T. Coskunet al., “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept,”Mol. Metab., vol. 18, pp. 3–14, Oct. 2018, doi: 10.1016/j.molmet.2018.09.009. S. Urvaet al., “The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying,”Diabetes Obes. Metab., vol. 25, no. 9, pp. 2784–2788, Sep. 2023, doi: 10.1111/dom.15167. G. Winkler, J. T. Kis, K. A. Kiss, and L. Schandl, “A GLP1-receptor-agonistáktól a glükagonreceptor-agonizmussal kiegészített hármashormonreceptor-aktiválásig.: Új távlatok a 2-es típusú diabetes és az elhízás kezelésében,”Orv. Hetil., vol. 164, no. 42, pp. 1656–1664, Oct. 2023, doi: 10.1556/650.2023.32894. T. M. Fraylinget al., “A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure,”Cell Rep., vol. 23, no. 2, pp. 327–336, Apr. 2018, doi: 10.1016/j.celrep.2018.03.070. T. Coskunet al., “Fibroblast Growth Factor 21 Corrects Obesity in Mice,”Endocrinology, vol. 149, no. 12, pp. 6018–6027, Dec. 2008, doi: 10.1210/en.2008-0816. J. P. Friaset al., “Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial,”Lancet Lond. Engl., vol. 392, no. 10160, pp. 2180–2193, Nov. 2018, doi: 10.1016/S0140-6736(18)32260-8. A. M. Jastreboffet al., “Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial,”N. Engl. J. Med., vol. 389, no. 6, pp. 514–526, Aug. 2023, doi: 10.1056/NEJMoa2301972. E. Harris, “Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss,”JAMA, vol. 330, no. 4, p. 306, Jul. 2023, doi: 10.1001/jama.2023.12055. A. Ray, “Retatrutide: a triple incretin receptor agonist for obesity management,”Expert Opin. Investig. Drugs, vol. 32, no. 11, pp. 1003–1008, Nov. 2023, doi: 10.1080/13543784.2023.2276754. I. Rix, C. Nexøe-Larsen, N. C. Bergmann, A. Lund, and F. K. Knop, “Glucagon Physiology,” inEndotext, K. R. Feingold, B. Anawalt, M. R. Blackman, A. Boyce, G. Chrousos, E. Corpas, W. W. de Herder, K. Dhatariya, K. Dungan, J. Hofland, S. Kalra, G. Kaltsas, N. Kapoor, C. Koch, P. Kopp, M. Korbonits, C. S. Kovacs, W. Kuohung, B. Laferrère, M. Levy, E. A. McGee, R. McLachlan, M. New, J. Purnell, R. Sahay, A. S. Shah, F. Singer, M. A. Sperling, C. A. Stratakis, D. L. Trence, and D. P. Wilson, Eds., South Dartmouth (MA): MDText.com, Inc., 2000. Accessed: Dec. 03, 2023. [Online]. A. Ceriello, S. Genovese, E. Mannucci, and E. Gronda, “Glucagon and heart in type 2 diabetes: new perspectives,”Cardiovasc. Diabetol., vol. 15, no. 1, p. 123, Aug. 2016, doi: 10.1186/s12933-016-0440-3. “File:Retatrutide.png - Wikipedia.”Commons.wikimedia.org, 6 July 2023, en.wikipedia.org/wiki/File:Retatrutide.png.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.